All lobbying filings
THE UNITED STATES PHARMACOPEIAL CONVENTION
THE UNITED STATES PHARMACOPEIAL CONVENTION filed a Q3 report for THE UNITED STATES PHARMACOPEIAL CONVENTION on October 20, 2025.
Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$80,000
What this organization spent lobbying with its own staff.
Reported using IRS section 6033(b)(8) definitions (method B): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Maryland
Government bodies contacted
2
Lobbying activity
3
S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain resilience. Issues regarding drug shortages and pharmaceutical supply chain resilience.
H.R. 5304, S.2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.
S. 2296 - National Defense Authorization Act for Fiscal Year 2026: Provisions regarding medicine supply chain.